Literature DB >> 15193362

Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise.

Marvin A Sackner1, Emerance M Gummels, Jose A Adams.   

Abstract

Increased shear stress to the endothelium increases activity of endothelial nitric oxide synthase (eNOS) with subsequent release of small quantities (nMol) of nitric oxide (NO) into the circulation. It occurs during moderate aerobic exercise mostly as a result of laminar shear stress and with whole body, periodic acceleration as a result of pulsatile shear stress. The latter is administered by means of a new, non-invasive, passive exercise device. Moderate exercise has long been known to alleviate the symptoms of fibromyalgia and chronic fatigue syndrome and in the current study, whole body, periodic acceleration did as well. Since NO through action of eNOS has potent anti-inflammatory properties mainly by suppressing nuclear factor kappabeta activity, it is hypothesized that both diseases have chronic inflammation as their basis. Whole body periodic acceleration can be applied separately or supplementary to aerobic exercise in the treatment of fibromyalgia and chronic fatigue syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193362     DOI: 10.1016/j.mehy.2004.01.025

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

Review 1.  Physical therapy and other nonpharmacologic approaches to fibromyalgia management.

Authors:  Ron Blehm
Journal:  Curr Pain Headache Rep       Date:  2006-10

Review 2.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

3.  Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol; Ozge Ardicoglu; Hulya Yildizhan
Journal:  Rheumatol Int       Date:  2005-11-10       Impact factor: 2.631

4.  No evidence for an association between the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and fibromyalgia syndrome.

Authors:  Belgin Alaşehirli; Seniz Demiryürek; Emine Arica; Savaş Gürsoy; Abdullah T Demiryürek
Journal:  Rheumatol Int       Date:  2006-09-02       Impact factor: 2.631

5.  Effect of aerobic exercise training on oxygen uptake and kinetics in patients with fibromyalgia.

Authors:  Mustafa Dinler; Demirhan Diracoglu; Erdem Kasikcioglu; Omer Sayli; Ata Akin; Cihan Aksoy; Ahmet Oncel; Ender Berker
Journal:  Rheumatol Int       Date:  2009-09-26       Impact factor: 2.631

6.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

7.  Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women.

Authors:  Ratchakrit Srikuea; T Brock Symons; Douglas E Long; Jonah D Lee; Yu Shang; Peter J Chomentowski; Guoqiang Yu; Leslie J Crofford; Charlotte A Peterson
Journal:  Arthritis Rheum       Date:  2013-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.